The research team at NDSS is excited to share that we will be hosting an Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting with the U.S. Food and Drug Administration (FDA) in June to discuss Down Syndrome-associated Alzheimer's Disease (DS-AD). The EL-PFDD meeting will give the FDA and other key stakeholders the opportunity to hear directly from patients, their families, caregivers, and patient advocates specifically about the symptoms of DS-AD, the impacts on daily lives, patient experiences with current available treatments, and hopes for future therapies.
Information Webinar
Join us for a FREE community webinar to learn about the upcoming EL-PFDD meeting on DS-AD. This session will provide an overview of the EL-PFDD meeting goals, explain how patient and caregiver experiences help inform drug development and regulatory decision-making, and share ways you can participate and make your voice heard.
Please note that this webinar has been postponed. If you have registered for the webinar, we will be in touch with details on the next steps.